MedTrace Logo

Efficacy and Safety of VMX Eye Drops for Dry Eye Disease

NCT07369375 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2026-01-29

No results posted yet for this study

Summary

This multicenter, randomized, double-blind study evaluates the safety and effectiveness of VMX eye drops in patients with dry eye disease. It aims to improve tear film stability, reduce dry eye symptoms, and enhance patients' quality of life compared to standard treatment.

Conditions

  • Dry Eye Disease (DED)

Interventions

DEVICE

VMX Eye Drops

VMX ophthalmic solution; the dosage is one drop in each eye three times a day for 56 days.

DEVICE

placebo eye drops

Sterile ophthalmic solution. The dosage is one drop in each eye three times a day for 56 days.

Sponsors & Collaborators

  • CROlife

    collaborator UNKNOWN

  • VISUfarma SpA

    lead INDUSTRY

Principal Investigators

  • Anna R Bigioni · CROlife

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-02
Primary Completion
2026-06-30
Completion
2026-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07369375 on ClinicalTrials.gov